Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
Massachusetts Eye and Ear Infirmary · Dana-Farber Cancer Institute
Abstract
Thalidomide (Thal) achieves responses even in the setting of refractory multiple myeloma (MM). Although increased angiogenesis in MM bone marrow and the antiangiogenic effect of Thal formed the empiric basis for its use in MM, we have shown that Thal and its immunomodulatory analogs (IMiDs) directly induce apoptosis or growth arrest of MM cells, alter adhesion of MM cells to bone marrow stromal cells, inhibit the production of cytokines (interleukin-6 and vascular endothelial growth factor) in bone marrow, and stimulate natural killer cell anti-MM immunity. In the present study, we demonstrate that the IMiDs trigger activation of caspase-8, enhance MM cell sensitivity to Fas-induced apoptosis, and…
Citation impact
- FWCI
- 14.00
- Percentile
- 100%
- References
- 40
Authors
9- NMNicholas MitsiadesCorresponding
Massachusetts Eye and Ear Infirmary, Dana-Farber Cancer Institute
- CSConstantine S. Mitsiades
Massachusetts Eye and Ear Infirmary, Dana-Farber Cancer Institute
- VPVassiliki Poulaki
Massachusetts Eye and Ear Infirmary, Dana-Farber Cancer Institute
- DCDharminder Chauhan
Massachusetts Eye and Ear Infirmary, Dana-Farber Cancer Institute
- PGPaul G. Richardson
Massachusetts Eye and Ear Infirmary, Dana-Farber Cancer Institute
Topics & keywords
- Stromal cell
- Apoptosis
- Thalidomide
- Bone marrow
- Cancer research
- Tumor necrosis factor alpha
- Angiogenesis
- Proteasome inhibitor
- Good health and well-being